PRLog (Press Release)
- Sep. 5, 2012 -
Tecan and Siloam Biosciences Inc. announce their intent to co-market a new automated low volume, high sensitivity microfluidic ELISA. The system is based on Tecan’s Freedom EVO® liquid handling technology and the Siloam Biosciences’
OptiMax™ microplate. It offers rapid, sensitive and specific chemifluorescence-
based ELISA procedures using exceedingly small sample volumes. The speed, sensitivity and small sample requirements are achieved as a result of the unique microfluidic design of the Optimiser™ technology. All reactions, including analyte capture and detection, occur within an ~5 μl microfluidic reaction chamber. The unique microchannel geometry and small reaction volume favor rapid reaction kinetics. A typical assay requires only a 5 μl sample and each reaction step is completed within 10 to 20 minutes. With wash times, substrate incubations and read times accounted for, a typical Optimiser technology-based ELISA can be completed within two hours. Exploiting these rapid reaction kinetics on a microscale, coupled with microplate automation on the Freedom EVO workstation, allows for extremely high sensitivity or very fast assays.
Automating the process with the Freedom EVO workstation further enhances Optimiser ELISA efficiency and increases throughput. The Freedom EVO automatically loads analytes and reagents into the wells of the microfluidic microplate, and allows the robotic manipulation of multiple OptiMax microplates. Automation with the Freedom EVO offers distinct performance benefits, including improved pipetting precision at very low volumes, precise control of dispensing times allowing for short incubation cycles, precise operation of the repeat load process dramatically improving sensitivity, and increased productivity allowing the user to attend to other tasks while the instrument is in operation. A fully integrated read-out of the chemifluorescent signal is provided by Tecan’s Infinite® M200 microplate reader.
Kevin Moore, Head of Applications and Solutions at Tecan, said: “We are delighted to be working with Siloam Biosciences and are looking forward to bringing our customers a new option for running automated ELISAs using the very exciting new technology of microplate-based microfluidics.”
Aniruddha Puntambekar, Chief Operating Officer at Siloam Biosciences Inc., added: “Tecan’s automation systems enhance the performance of OptiMax automation plates and we are pleased to be able to offer improvements to ELISA users based on Tecan’s automation expertise. Together, our technologies provide significant advances to immunoassay testing that will benefit customers of both companies.”
To find out more about Tecan’s OptiMax solutions, visit www.tecan.com/
To find out more about OptiMax products, visit www.siloambio.com
For more information please contact
Tecan Trading AG
Cornelia Kegele / Antonietta Allocca
Seestrasse 103, CH-8708 Männedorf
Tel +41 (0)44 922 81 11, Fax +41 (0)44 922 81 12
For more information about Siloam Biosciences, please contact
Aniruddha Puntambekar, Chief Operating Officer (email@example.com)
is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters:
TECZn.S/Swiss security number: 1210019).
About Siloam Biosciences Inc.
Siloam Biosciences, Inc., is focused on developing the next generation of diagnostic systems using innovative microfluidics for immunoassay based diagnostics. The company has developed the novel Optimiser™ microfluidic platform with vastly superior performance to current 96-well microplates;
specifically ~ 20 times reduction in sample/reagent and tremendous assay speeds (30 minutes to two hours as opposed to 8 hours!). Optimiser™/OptiMax™
plates are currently marketed as a solution for rapid, ultra-sensitive and cost effective immunoassays in the life sciences research sector. With the potential for 20-1000x higher sensitivity, we envision the OptiMax™ as THE key component used with currently available automated ELISA diagnostic systems. This represents the first pathway towards an automated diagnostic platform from Siloam’s microfluidic technology suite. The revolutionary Optimiser™ platform also serves as the development vehicle for Siloam’s lab-on-a-chip based Point-of-Care Test (POCT) platform allowing for the first ever seamless approach from lab to patient bedside.Photo: